COLUMBIA, MD and TORONTO, ON--(Marketwired - Mar 6, 2014) - Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
The new patent, EP1581145, was granted by the EPO to John Mon, COO, and Dr. Alan Fenn, co-inventor of the APA focusing technology, and is assigned to Medifocus. The title of the patent is "Thermotherapy Apparatus for the Treatment and Preventions of Cancer in Male and Female Patients and Cosmetic Ablation of Tissue" and is a focused heat apparatus for, not only the treatment, but also the prevention of cancer tissues and, more specifically, breast cancers. Another embodiment of this patent is for the use of the apparatus for the minimal and non-invasive cosmetic applications specifically to destroy and/or melt fatty tissue as a potential to replace traditional invasive liposuction procedures. It can also be used as a potential apparatus to smooth out the contours and dimpling caused by cellulite.
Medifocus is currently using its Adaptive Phase Array (APA) focused heat technology in its US FDA and Health Canada Pivotal Phase III study for the treatment of locally advanced large breast tumors.
About Medifocus, Inc.
Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drugs Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus' APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers. Please visit www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.
Forward-Looking Statements and Information
This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect the structure and the proceeds of the Offering and the expected use of the proceeds. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, Medifocus disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.